HK) is thrilled to unveil groundbreaking data on its internally developed ivonescimab (a first-in-class PD-1/VEGF bispecific antibody ... first-line treatment for PD-L1 positive (PD-L1 TPS ...
5.82 months with pembrolizumab in 1L PD-L1 positive advanced NSCLC ... developed ivonescimab (a first-in-class PD-1/VEGF bispecific antibody) at the IASLC 2024 World Conference on Lung Cancer ...
HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab ... and across tumor stage and PD-L1 expression subgroups. Ivonescimab + chemotherapy cohort: pCR rate ...